CB Scientific (CB Scientific) Notes Receivable : $0.00 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is CB Scientific Notes Receivable?

CB Scientific's Notes Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

CB Scientific's annual Notes Receivable increased from Mar. 2021 ($0.00 Mil) to Mar. 2022 ($0.04 Mil) but then declined from Mar. 2022 ($0.04 Mil) to Mar. 2023 ($0.00 Mil).

CB Scientific Notes Receivable Historical Data

The historical data trend for CB Scientific's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CB Scientific Notes Receivable Chart

CB Scientific Annual Data

Trend

Mar21

Mar22

Mar23

Notes Receivable

0.04

CB Scientific Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Notes Receivable	Get a 7-Day Free Trial							-	-	-	-	-

CB Scientific Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

CB Scientific Notes Receivable Related Terms

Thank you for viewing the detailed overview of CB Scientific's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

CB Scientific (CB Scientific) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CB Scientific Inc (OTCPK:CBSC) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

10845 Griffith Peak Drive, Suite 200, Las Vegas, NV, USA, 89135

Website

https://www.cbscientificinc.com

CB Scientific Inc through its U.S. and international subsidiaries provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.